CEO Sets Strides For Growth With Endo Execs
Stelis Signals Listing, Focus Shift
Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing.
You may also be interested in...
Strides Fights COVID-19-Led Sales Slump With Endo Assets, Sputnik V
After a COVID-19-led manufacturing halt at its India facility and a slowdown in US launches hit Strides during the first quarter of FY22, the Indian firm is trying to fight back with an acquisition of assets from Endo and a growth strategy for Stelis Biopharma’s vaccines business, led by Sputnik V.
Strides Considers Sputnik Light Production
Strides will consider making RDIF’s Sputnik Light vaccine after filling orders for Sputnik V, which it expects to launch in October. The COVID-19 portfolio is being expanded and the Indian company is set to make a Para IV filing for a diabetes product in December, CEO R Ananthanarayanan tells Scrip.
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.